Genetic Technologies has signed an exclusive worldwide license agreement with The University of Melbourne to develop and market a novel colorectal cancer (CRC) risk assessment test.

Under the terms of the agreement, Genetic Technologies is tasked with the commercial development of the test, as well as collaborate with The University of Melbourne to undertake research using the university’s experience in single-nucleotide polymorphism (SNP)-based risk assessment and risk model development.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Genetic Technologies executive director and chief executive officer Eutillio Buccilli said: "This is an exciting time for the Company as we commence this strategic alliance with The University of Melbourne.

"The relationship with the University is comprehensive and highlights our overall corporate mission to become a leader in the genomics focused oncology diagnostics' industry while enhancing our pipeline of risk assessment products."

“The relationship with the University is comprehensive and highlights our overall corporate mission to become a leader in the genomics focused oncology diagnostics' industry while enhancing our pipeline of risk assessment products."

The technology behind the test was developed by Professor Mark Jenkins and his research team at the University's Centre for Epidemiology and Biostatistics which is similar to Genetic Technologies’ BREVAGenplus test.

BREVAGenplus is a test that will determine the risk for developing sporadic (non-hereditary) breast cancer by examining a cheek swab that is collected at the health care provider’s office.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The similarity between the technology under development and the BREVAGenplus test will allow an easy integration of the new test into the company’s existing infrastructure and processes.

The CRC risk assessment tool is expected to facilitate better targeting of existing screening modalities and improving compliance among patients at risk of developing CRC.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact